Newsroom | 5579 results
Sorted by: Latest
-
Le TFG-001, une nouvelle thérapie cellulaire à base de microtissus neuronaux en 3D, démontre une fonctionnalité et une réinnervation supérieures dans le traitement de la maladie de Parkinson
BORDEAUX, France--(BUSINESS WIRE)--TreeFrog Therapeutics, une société de biotechnologie spécialisée dans la médecine régénérative qui développe des thérapies cellulaires de nouvelle génération, a annoncé aujourd’hui qu’elle présenterait de nouvelles données précliniques sur le TFG-001 lors de la 7e Conférence mondiale sur la maladie de Parkinson. Le TFG-001, une thérapie cellulaire à base de microtissus neuronaux 3D, a démontré une libération rapide de dopamine et une réinnervation étendue déri...
-
TFG-001, eine neuartige 3D-Zelltherapie auf Basis von neuronalem Mikrogewebe, zeigt überlegene Funktionalität und Reinnervation bei der Parkinson-Krankheit
BORDEAUX, Frankreich--(BUSINESS WIRE)--TreeFrog Therapeutics, ein Biotech-Unternehmen im Bereich der regenerativen Medizin, das Zelltherapien der nächsten Generation entwickelt, gab heute bekannt, dass es auf der 7. Welt-Parkinson-Konferenz neue präklinische Daten zu TFG-001 vorstellen wird. TFG-001, eine 3D-neural-mikrogewebezelltherapie, zeigte in mehreren fortgeschrittenen translationalen Parkinson-Modellen eine schnelle Dopaminfreisetzung und eine umfassende, vom Transplantat ausgehende Rei...
-
Samenvatting: TFG-001, een nieuwe 3D neurale microweefsel-celtherapie, bewijst een uitstekende werking en staat in voor herbezenuwing bij de ziekte van Parkinson
BORDEAUX, Frankrijk--(BUSINESS WIRE)--TreeFrog Therapeutics, een biotech-bedrijf gericht op regeneratieve geneeskunde dat celtherapieën van de nieuwe generatie ontwikkelt, maakte vandaag bekend dat het bedrijf nieuwe preklinische gegevens over TFG-001 zal voorstellen tijdens de 7e World Parkinson’s Conference. TFG-001, een 3D neurale microweefsel-celtherapie, bewees snelle afgifte van dopamine en uitgebreide herbezenuwing afkomstig van transplantaten bij verschillende translationele modellen va...
-
Riassunto: TFG-001, l'innovativa terapia cellulare basata su microtessuti neurali 3D, dimostra capacità funzionali e di reinnervazione superiori nel Parkinson
BORDEAUX, Francia--(BUSINESS WIRE)--TreeFrog Therapeutics, biotech specializzata nella medicina rigenerativa e nello sviluppo di terapie cellulari di prossima generazione, oggi ha annunciato che presenterà nuovi dati preclinici su TFG-001 alla 7a conferenza mondiale sulla malattia di Parkinson. TFG-001 è una terapia cellulare basata su microtessuti neurali 3D che ha dimostrato un rilascio rapido di dopamina e un'estesa reinnervazione a seguito di graft in diversi modelli traslazionali della mal...
-
Resumen: TFG-001, una novedosa terapia celular basada en microtejidos neuronales tridimensionales, demuestra una funcionalidad y una reinervación superiores en el tratamiento de la enfermedad de Parkinson
BURDEOS, Francia--(BUSINESS WIRE)--TreeFrog Therapeutics, una empresa biotecnológica dedicada a la medicina regenerativa que desarrolla terapias celulares de última generación, ha anunciado hoy que presentará nuevos datos preclínicos sobre el TFG-001 en la 7.ª World Parkinson's Conference. TFG-001, una terapia celular basada en microtejidos neuronales 3D, ha demostrado una rápida liberación de dopamina y una reinervación extensa derivada del injerto en múltiples modelos traslacionales avanzados...
-
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease
BORDEAUX, France--(BUSINESS WIRE)--TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. Th...
-
Hyperfine Announces Presentation of Results from the PRIME Study Showing Portable MRI Substantially Reduces Time to Imaging in Emergency Departments
GUILFORD, Conn.--(BUSINESS WIRE)--PRIME study results show bedside portable MRI cut order-to-scan time vs conventional MRI and identified critical ED findings....
-
Zai Lab Announces Changes to Senior Leadership Team
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced changes to its senior leadership team aimed at strengthening operational performance and efficiency. As part of these changes, the Board has made the decision that Josh Smiley, President and COO, will no longer be with the Company, effective Friday, May 22. "I want to thank Josh for his contributions to Zai Lab over the past three and a half years and wish him well in his future endeavors,"...
-
LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Stefano Folli will join the Company as incoming President, Cardiopulmonary (CP), effective June 1, succeeding Franco Poletti, who will retire on July 31. Folli will partner closely with Poletti over the coming months to ensure a seamless leadership transition before assuming full responsibility for the business on August 1. Folli will join the LivaNova Executive Leadership Tea...
-
Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 at 3:10 p.m. EDT. Audio webcasts and replays of available presentat...
